Quantum Biopharma's (QNTM) Sell (E+) Rating Reaffirmed at Weiss Ratings

Key Points

• Weiss Ratings has reaffirmed a "sell (e+)" rating for Quantum Biopharma (NASDAQ: QNTM), reflecting ongoing concerns about the company's performance.
• Quantum Biopharma's stock is set for a 2-for-1 split on October 27th, which follows a period of volatility in its share price.
• The company reported an earnings miss of ($3.23) EPS, significantly below the consensus estimate, indicating potential challenges ahead for investors.

Quantum Biopharma (NASDAQ:QNTM - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by investment analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Separately, Singular Research upgraded shares of Quantum Biopharma to a "moderate buy" rating in a report on Wednesday, June 18th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of "Sell".

Quantum Biopharma Price Performance

NASDAQ QNTM opened at $15.77 on Wednesday. The stock has a market capitalization of $60.18 million, a PE ratio of -1.12 and a beta of 0.70. Quantum Biopharma has a 1 year low of $2.70 and a 1 year high of $38.25. The business's 50-day moving average is $18.88 and its 200 day moving average is $15.66.

Shares of Quantum Biopharma are scheduled to split on the morning of Monday, October 27th. The 2-1 split was recently announced. The newly minted shares will be distributed to shareholders after the closing bell on Sunday, October 26th.

Quantum Biopharma (NASDAQ:QNTM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($3.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($3.06). As a group, equities research analysts anticipate that Quantum Biopharma will post -3.27 earnings per share for the current year.

Institutional Investors Weigh In On Quantum Biopharma

An institutional investor recently bought a new position in Quantum Biopharma stock. Steward Partners Investment Advisory LLC acquired a new position in Quantum Biopharma Ltd. (NASDAQ:QNTM - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,100 shares of the company's stock, valued at approximately $63,000. Steward Partners Investment Advisory LLC owned approximately 0.11% of Quantum Biopharma at the end of the most recent reporting period. Institutional investors own 1.24% of the company's stock.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.